79570-57-3

Basic information

• Product Name: 9-(hydroxymethyl)-2,4,8,9-tetrazabicyclo[4.3.0]nona-1,3,6-trien-5-one
• Synonyms: 9-(hydroxymethyl)-2,4,8,9-tetrazabicyclo[4.3.0]nona-1,3,6-trien-5-one
• CAS NO: 79570-57-3
• Molecular Formula: C₆H₆N₄O₂
• Molecular Weight: 166.14
• Mol File: 79570-57-3.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 354.8°C at 760 mmHg
• Flash Point: 168.4°C
• Appearance: /
• Density: 1.81g/cm³
• Vapor Pressure: 1.87E-06mmHg at 25°C
• Refractive Index: 1.821
• CAS DataBase Reference: 9-(hydroxymethyl)-2,4,8,9-tetrazabicyclo[4.3.0]nona-1,3,6-trien-5-one(CAS DataBase Reference)
• NIST Chemistry Reference: 9-(hydroxymethyl)-2,4,8,9-tetrazabicyclo[4.3.0]nona-1,3,6-trien-5-one(79570-57-3)
• EPA Substance Registry System: 9-(hydroxymethyl)-2,4,8,9-tetrazabicyclo[4.3.0]nona-1,3,6-trien-5-one(79570-57-3)

Safety Data

• Hazardous Substances Data: 79570-57-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H6N4O2/c11-3-10-5-4(1-9-10)6(12)8-2-7-5/h1-2,9,11H,3H2

Upstream product

• 50-00-0 formaldehyd 
• 315-30-0 Allopurinol 
• 184789-03-5 1,2-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 

Downstream Products

• 98203-96-4 1-(DL-Phenylalanyloxymethyl)allopurinol (hydrobromide) 
• 98846-65-2 1-(Benzoyloxymethyl)allopurinol 

Relevant articles and documents

With prevention and treatment of hyperuricemia or Gout compound and its preparation method and application

The invention discloses a compound with an effect of treating and preventing hyperuricemia or gout and a preparation method as well as application thereof. The general structural formula of the compound is shown as a formula (I); the proportion of lesinuard and an allopurinol medicament can be effectively controlled by the series of the compounds, the dose and frequency are reduced, the effect of combination medication can be achieved by single-time medication, meanwhile the preparation process can be simplified, and the production cost is saved; since a linking group exists between the two compounds, the compound can only be hydrolyzed into two medicaments under the action of an enzyme for a certain time after the compound is orally taken and absorbed; thus, the half-life in vivo of the compound is increased by the process, namely the medicament achieve a slow release effect through a chemical coupling method.